Navigation Links
The IMF says journal editorial documents dramatic increase in survival since the 1980s
Date:9/11/2008

North Hollywood, CA September 11, 2008 - The International Myeloma Foundation (IMF)supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicianstoday said survival outcomes have improved dramatically for patients with multiple myeloma, cancer in the bone marrow that affects blood cell production. Writing in the October 10th edition of the Journal of Clinical Oncology*, IMF chairman Brian G.M. Durie, M.D., notes that 25 years ago only 48 percent to 66 percent of myeloma patients survived two years, depending on which treatment was used. By contrast today, two-year survival rates are around 90 percent.

"What has changed is not the research capability, it is the availability of potent new classes of drugs without the side effects typically associated with chemotherapy," says Dr. Durie. "The successful agents in myeloma are multifunctional with a diverse impact on cell function and pathways. This may well be the secret of success."

The editorial explains that drug design was spurred by the discovery that thalidomide, originally developed as a sedative, was effective against myeloma through multiple mechanisms of action. As a result we have potent, targeted drugs such as Revlimid® and Velcade®, with improved outcomes.

"The benefits and comparisons are particularly interesting looking at the results with lenalidomide (Revlimid) plus low-dose dexamethasone (steroid) compared with prior results with interferon and levamisole. There is essentially a doubling of survival at two years, with preliminary evidence that this survival will be maintained for at least three to four years."

Dr. Durie notes these achievements with myeloma are now benefiting a wide range of blood cancers as these drugs are being tested in non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other blood cancers. In the editorial he says the next step is to identify new agents with
'/>"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2

Related biology news :

1. News tips from the Journal of Neuroscience
2. Tips from the Journals of the American Society for Microbiology
3. Story ideas from the Journal of Lipid Research
4. Highlights from the September 2007 Journal of the American Dietetic Association
5. AGU journal highlights -- Sept. 6, 2007
6. Springer will publish Journal of Coastal Conservation
7. ESA celebrates 100 years of insect science journals
8. Springer and the New York Botanical Garden Press join forces to publish botanical journals
9. 200 journals join in theme issues on poverty and human development
10. New ETH Zurich article published in scientific journal Nature
11. Media highlights in the November issues of Biophysical Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... set a "mouse TRAP" to capture the early signs ... published in the Journal of Clinical Investigation . ... TRAP to extract cellular and genetic information from a ... the Rockefeller Institute for Medical Research in 2008, TRAP ... or ribosomes, of the cell type of interest. Scientists ...
(Date:7/11/2014)... Shenzhen, China Researchers from Salk Institute for Biological ... time evaluated the safety and reliability of the ... a new method, TALEN-HDAdV, which could significantly increased ... (hiPSC). This study published online in Cell ... for stem cell-based gene therapy. , The combination ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... beauty products. According to the beauty industry liposomes ... skin and release the active ingredients so that they ... the skin. Research from University of Southern ... transporting themselves deep into the skin, and thus they ...
... Amsterdam, NL, 19 February 2013 Raman spectroscopy ... and is a powerful tool for tissue classification ... challenges to using the method in a clinical ... wavelength-modulated Raman spectroscopy, opening the door to wider ...
... A new species of scorpion, Vaejovis brysoni, was found in ... scorpion of the same group also inhabits this mountain range, ... group species distributed on the same mountain. The study ... Zookeys . These mountains overlook the city of ...
Cached Biology News:Don't trust liposomes in your beauty products 2Breakthrough study opens door to broader biomedical applications for Raman spectroscopy 2
(Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
(Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, today,announced that Ron ... Russell, Vice President, Finance, will be attending the,Goldman ... in New,York City in order to meet with ...
... Nektar,Therapeutics, (Nasdaq: NKTR ) President and Chief Executive ... upcoming UBS 2008 Global Life,Sciences Conference in New York ... 23, 2008 at 10:30 a.m. ET., The presentation ... posted,on the Investor Relations, Events Calendar section of the ...
... Finger Nuclease Platform enables Precise, Permanent, and ... Heritable Modification of the Genome, ... CompoZr(TM) platform of zinc finger nuclease (ZFN),reagents. The CompoZr ZFN ... to target and precisely manipulate the genome,of living cells, resulting ...
Cached Biology Technology:Sigma-Aldrich Launches Breakthrough Genome-Editing Tools 2Sigma-Aldrich Launches Breakthrough Genome-Editing Tools 3
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Biology Products: